Enquiries to Ministry of Health
0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Form SA2533
March 2026

APPLICANT (stamp or sticker acceptable)	**PATIENT** NHI:	**REFERRER** Reg No: .....
Reg No:	First Names:	First Names: .....
Name:	Surname:	Surname: .....
Address:	DOB:	Address: .....
.....	Address:	.....
.....	.....	.....
Fax Number:	.....	Fax Number: .....

Faricimab

Initial application — diabetic macular oedema
Applications from any relevant practitioner. Approvals valid for 4 months.
Prerequisites(tick boxes where appropriate)

- ☐ Patient has centre involving diabetic macular oedema (DMO)

and

- ☐ Patient's disease is nonresponsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly

and

- ☐ Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision

and

- ☐ Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers

and

- ☐ There is no centre-involving sub-retinal fibrosis or foveal atrophy

and

- ☐ Patient has not previously been treated with aflibercept for longer than 3 months

Renewal — diabetic macular oedema

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 12 months.
Prerequisites(tick boxes where appropriate)

- ☐ There is stability or two lines of Snellen visual acuity gain

and

- ☐ There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid)

and

- ☐ Patient's vision is 6/36 or better on the Snellen visual acuity score

and

- ☐ There is no centre-involving sub-retinal fibrosis or foveal atrophy

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....
Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	**PATIENT** NHI:	**REFERRER** Reg No: .....
Reg No:	First Names:	First Names: .....
Name:	Surname:	Surname: .....
Address:	DOB:	Address: .....
.....	Address:	.....
.....	.....	.....
Fax Number:	.....	Fax Number: .....

Faricimab *- continued*

Initial application — wet age related macular degeneration
Applications from any relevant practitioner. Approvals valid for 3 months.
Prerequisites(tick boxes where appropriate)

- ☐ Wet age-related macular degeneration (wet AMD)
  or
- ☐ Polypoidal choroidal vasculopathy
  or
- ☐ Choroidal neovascular membrane from causes other than wet AMD

and

- ☐ The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab
  or
- ☐ There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart

and

- ☐ There is no structural damage to the central fovea of the treated eye

and

- ☐ Patient has not previously been treated with ranibizumab or aflibercept for longer than 3 months

Renewal — wet age related macular degeneration

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 12 months.
Prerequisites(tick boxes where appropriate)

- ☐ Patient's vision is 6/36 or better on the Snellen visual acuity score

and

- ☐ There is no structural damage to the central fovea of the treated eye

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....